Patents by Inventor John F. Burd
John F. Burd has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20090303477Abstract: A reagent-less test strip system including a spectrometer; a test strip with a membrane for receiving a test sample, the membrane configured to separate the test sample into at least the following: one or more components that would interfere with measurement by the spectrometer and one or more components including one or more analytes that are to be measured by the spectrometer. The spectrometer measures from the test strip the separated one or more components including one or more analytes that are to be measured by the spectrometer without measuring the separated one or more components that would interfere with measurement by the spectrometer.Type: ApplicationFiled: June 10, 2008Publication date: December 10, 2009Inventor: John F. Burd
-
Patent number: 6975892Abstract: The present invention is related to non-invasive methods and instruments to detect the level of analyte concentrations in the tissue of a subject by measuring electromagnetic radiation signatures from the subject's conjunctiva. The spectra of mid-infrared radiation emitted from a subject's body are altered corresponding to the concentration of various compounds within the radiating tissue. In one aspect of the invention, an instrument floods the conjunctiva of the subject with electromagnetic radiation in the mid-infrared range and measures analyte concentrations based on mid-infrared radiation reflected back to the instrument.Type: GrantFiled: April 14, 2004Date of Patent: December 13, 2005Assignee: Oculir, Inc.Inventors: John F. Burd, Gary Krantz, Jacob Fraden, Charles Kramer, Bart Chapman, William Sell
-
Patent number: 6968222Abstract: The present invention is related to optical non-invasive methods and instruments to detect the level of analyte concentrations in the tissue of a subject. The spectra of mid-infrared radiation emitted from a subject's body are altered corresponding to the concentration of various compounds within the radiating tissue. In one aspect of the invention, an instrument floods a body surface of the subject, such as the subject's eye, with radiation in the mid-infrared range and measures analyte concentrations based on mid-infrared radiation reflected back to the instrument.Type: GrantFiled: May 2, 2003Date of Patent: November 22, 2005Assignee: Oculir, Inc.Inventors: John F. Burd, Jacob Fraden, Charles E. Kramer, Gary Krantz, William Sell
-
Patent number: 6958129Abstract: The present invention is directed to a single test system and method for determining the integrated glycemic condition of a subject by measuring the concentration of glucose and the level of protein-bound glucose in a subject's body fluid, such as whole blood. The glucose concentration is indicative of the subject's immediate glycemic condition, whereas the protein-bound glucose concentration is indicative of either intermediate or long-term glycemic condition. Optionally, other analytes indicative of glycemic condition, such as ketone bodies or fatty acid derivatives, can also be measured. The present invention also provides a method of diagnosing diabetes. The invention additionally provides a method for analyzing the concentration of fructosamine in less than or equal to five minutes without the use of a reaction accelerator.Type: GrantFiled: September 19, 2003Date of Patent: October 25, 2005Assignee: LifeScan, Inc.Inventors: Robert S. Galen, John F. Burd, Talei Hoblitzell, Gebhard Neyer
-
Patent number: 6958039Abstract: The present invention is related to optical non-invasive methods and instruments to detect the level of analyte concentrations in the tissue of a subject. The spectra of mid-infrared radiation emitted from a subject's body are altered corresponding to the concentration of various compounds within the radiating tissue. In one aspect of the invention, an instrument measures the level of mid-infrared radiation from the subject's body surface, such as the eye, and determines a specific analyte's concentration based on said analyte's distinctive mid-infrared radiation signature.Type: GrantFiled: April 14, 2004Date of Patent: October 25, 2005Assignee: Oculir, Inc.Inventors: John F. Burd, Gary Krantz, William Sell
-
Publication number: 20040265941Abstract: The present invention is directed to a single test system and method for determining the integrated glycemic condition of a subject by measuring the concentration of glucose and the level of protein-bound glucose in a subject's body fluid, such as whole blood. The glucose concentration is indicative of the subject's immediate glycemic condition, whereas the protein-bound glucose concentration is indicative of either intermediate or long-term glycemic condition. Optionally, other analytes indicative of glycemic condition, such as ketone bodies or fatty acid derivatives, can also be measured. The present invention also provides a method of diagnosing diabetes. The invention additionally provides a method for analyzing the concentration of fructosamine in less than or equal to five minutes without the use of a reaction accelerator.Type: ApplicationFiled: September 19, 2003Publication date: December 30, 2004Inventors: Robert S. Galen, John F. Burd, Talei Hoblitzell, Gebhard Neyer
-
Publication number: 20040220457Abstract: The present invention is related to optical non-invasive methods and instruments to detect the level of analyte concentrations in the tissue of a subject. The spectra of mid-infrared radiation emitted from a subject's body are altered corresponding to the concentration of various compounds within the radiating tissue. In one aspect of the invention, an instrument floods a body surface of the subject, such as the subject's eye, with radiation in the mid-infrared range and measures analyte concentrations based on mid-infrared radiation reflected back to the instrument.Type: ApplicationFiled: May 2, 2003Publication date: November 4, 2004Inventors: John F. Burd, Jacob Fraden, Charles E. Kramer, Gary Krantz, William Sell
-
Publication number: 20040220458Abstract: The present invention is related to optical non-invasive methods and instruments to detect the level of analyte concentrations in the tissue of a subject. The spectra of mid-infrared radiation emitted from a subject's body are altered corresponding to the concentration of various compounds within the radiating tissue. In one aspect of the invention, an instrument measures the level of mid-infrared radiation from the subject's body surface, such as the eye, and determines a specific analyte's concentration based on said analyte's distinctive mid-infrared radiation signature.Type: ApplicationFiled: April 14, 2004Publication date: November 4, 2004Inventors: John F. Burd, Gary Krantz, William Sell
-
Publication number: 20040018628Abstract: An integrated test system and method for assessing drug effectiveness and the organ function of a subject by measuring the concentration of organ marker, drug and/or one or more metabolites in a subject's body fluid.Type: ApplicationFiled: July 17, 2003Publication date: January 29, 2004Inventors: John F. Burd, Steven V. Edelman
-
Patent number: 6670192Abstract: The present invention is directed to a single test system and method for determining the integrated glycemic condition of a subject by measuring the concentration of glucose and the level of protein-bound glucose in a subject's body fluid, such as whole blood. The glucose concentration is indicative of the subject's immediate glycemic condition, whereas the protein-bound glucose concentration is indicative of either intermediate or long-term glycemic condition. Optionally, other analytes indicative of glycemic condition, such as ketone bodies or fatty acid derivatives, can also be measured. The present invention also provides a method of diagnosing diabetes. The invention additionally provides a method for analyzing the concentration of fructosamine in less than or equal to five minutes without the use of a reaction accelerator.Type: GrantFiled: January 5, 2000Date of Patent: December 30, 2003Inventors: Robert S. Galen, John F. Burd, Talei Hoblitzell, Gebhard Neyer
-
Patent number: 6627153Abstract: A test device that assesses the concentration of an organ marker, a drug marker and a metabolite associated with the drug/organ interaction.Type: GrantFiled: August 31, 2001Date of Patent: September 30, 2003Inventors: John F. Burd, Steven V. Edelman
-
Patent number: 6558321Abstract: The present invention relates generally to the field of healthcare. Particularly, in the remote monitoring and modulation of a medical device on or in a subject. The present invention provides both systems and methods for remote monitoring of a subject, as well remote treatment of a subject (e.g. modulation of a medical device).Type: GrantFiled: August 11, 2000Date of Patent: May 6, 2003Assignee: DexCom, Inc.Inventors: John F. Burd, Peter G. Jacobs, William J. Sell, Mark C. Shults
-
Patent number: 6027692Abstract: The present invention is directed to a single test system and method for determining the integrated glycemic condition of a subject by measuring the concentration of glucose and the level of protein-bound glucose in a subject's body fluid, such as whole blood. The glucose concentration is indicative of the subject's immediate glycemic condition, whereas the protein-bound glucose concentration is indicative of either intermediate or long-term glycemic condition. Optionally, other analytes indicative of glycemic condition, such as ketone bodies or fatty acid derivatives, can also be measured. The present invention also provides a method of diagnosing diabetes. The invention additionally provides a method for analyzing the concentration of fructosamine in less than or equal to five minutes without the use of a reaction accelerator.Type: GrantFiled: December 12, 1996Date of Patent: February 22, 2000Assignee: LXN CorporationInventors: Robert S. Galen, John F. Burd, Talei Hoblitzell, Gebhard Neyer
-
Patent number: 5885839Abstract: The present invention provides a method of using a reflectance-reading device to determine an initiation time point for measuring the chemical reaction of an analyte from a biological liquid sample on a test surface. The initiation time point is determined by using a device to read a reflectance of a test surface at a plurality of time points, and calculating the K/S ratio of the test surface at each time point according to the Kubelka-Munk equation. As the device continues to calculate a K/S ratio for each time point, the device monitors the rate of change of the K/S ratio with respect to time. The device then determines the initiation time point to be when the rate of change of the K/S ratio is maximal. The present invention also provides a method of measuring the concentration of an analyte on a test surface. The concentration is measured by determining an initiation time point according to the method described above and then measuring the concentration of the analyte at a variable end point.Type: GrantFiled: April 15, 1997Date of Patent: March 23, 1999Assignee: LXN CorporationInventors: Paul J. Lingane, John F. Burd, Karen A. Goins, Michael D. Goins
-
Patent number: 5695949Abstract: The present invention is directed to a single test system and method for determining the integrated glycemic condition of a subject by measuring the concentration of glucose and the level of protein-bound glucose in a subject's body fluid, such as whole blood. The glucose concentration is indicative of the subject's immediate glycemic condition, whereas the protein-bound glucose concentration is indicative of either intermediate or long-term glycemic condition. Optionally, other analytes indicative of glycemic condition, such as ketone bodies or fatty acid derivatives, can also be measured. The present invention also provides a method of diagnosing diabetes. The invention additionally provides a method for analyzing the concentration of fructosamine in less than or equal to five minutes without the use of a reaction accelerator.Type: GrantFiled: April 7, 1995Date of Patent: December 9, 1997Assignee: LXN Corp.Inventors: Robert S. Galen, John F. Burd, Talei Hoblitzell, Gebhard Neyer
-
Patent number: 5639672Abstract: The present invention relates to a method for electrochemically measuring the concentration of fructosamine, or its high alkalinity eneaminol tautomer in a body fluid sample.Type: GrantFiled: October 16, 1995Date of Patent: June 17, 1997Assignee: LXN CorporationInventors: John F. Burd, Gebhard Neyer
-
Patent number: 5470752Abstract: The present invention is directed to a multi-layer test device and method for analyzing the concentration of fructosamine in a liquid sample. The multi-layer test device has a buffer layer containing a buffer having a pH value of at least 9 which is either superposed above or juxtaposed to an indicator layer containing an indicator capable of being reduced by fructosamine. Supporting the buffer layer, the indicator layer, and any additional layers in the multi-layer device is at least one support member which optionally has a detection aperture for analyzing the concentration of fructosamine on the indicator layer. An additional support member having a sample aperture can be used. Where two support members are used the multi-layers are sandwiched between the first support member having a sample aperture and the second support member optionally having a detection aperture.Type: GrantFiled: June 29, 1994Date of Patent: November 28, 1995Assignee: LXN CorporationInventors: John F. Burd, Talei Hoblitzell, Gebhard Neyer
-
Patent number: 5082768Abstract: An attenuator is included in a reagent medium of a luminescent specific-binding assay to suppress undesirable extraneous light. In one such assay, an analyte in a sample is reacted with a specific binding partner attached to a solid surface, forming an immobilized pair at the surface. One member of the immobilized pair is then allowed to react with a specific binding partner previously conjugated with one component of a luminescent reaction system, and the remaining components are provided in the reagent medium. The resulting light emitted in the luminescent reaction is recorded on photographic film or other photodetector as a measure of the presence and quantity of the analyte in the sample.Type: GrantFiled: December 28, 1990Date of Patent: January 21, 1992Assignee: Mast Immunosystems, Inc.Inventors: John F. Burd, John W. Dyminski, Vincent A. Marinkovich
-
Patent number: 4743541Abstract: A luminescent substrate preparation having a concentration of catalytic inhibitors of less than about 100 ppm. The preparation is obtained by heating commercial grade luminol in a basic solution, crystallizing the luminol and separating the luminol crystals from the boiled solution. The heating, crystallization and separation steps are preferably repeated sequentially at least four times, with the starting material for each sequence after the first being the luminol preparation produced in the previous sequence. The luminol preparation has an enhanced pattern of activity, in that light output is substantially constant over a period of at least about one hour, with the intensity of light emitted by the preparation being at least about ten times that of commercially available luminol. Because of these enhanced characteristics, the luminol preparation is particularly adapted for use as a tag in specific binding assays where the concentration of analyte to be detected is low.Type: GrantFiled: July 17, 1985Date of Patent: May 10, 1988Assignee: Mast Immunosystems, Inc.Inventors: Keith W. Higgins, Christopher R. Brown, John F. Burd
-
Patent number: 4650771Abstract: Immunogens for preparing antibodies against the drug lidocaine and related compounds, labeled conjugates, synthetic intermediates, and the use of such antibodies and labeled conjugates in immunoassays for determining lidocaine and such related compounds. The immunogens comprise lidocaine or an analog thereof coupled through one of the aromatic methyl groups to a conventional immunogenic carrier. The antibodies and labeled conjugates are particularly useful in homogeneous nonradioisotopic immunoassays for measuring lidocaine or its analogs in biological fluids such as serum.Type: GrantFiled: November 4, 1983Date of Patent: March 17, 1987Assignee: Miles Laboratories, Inc.Inventors: Robert T. Buckler, John F. Burd, Stephan G. Thompson